Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity: Q1 Earnings Mark A Possible Turnaround For The Company (Rating Upgrade)
Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.
Why Doximity Stock Was Soaring Today
Doximity beat estimates on the top and bottom lines. The company continues to report strong margins.
Why Is Doximity (DOCS) Stock Up 30% Today?
Doximity (NYSE: DOCS ) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share.
Doximity Stock Jumps 31%. Here's Why.
The medical platform's quarterly result beat expectations on both top and bottom lines, and is also leveraging AI to appeal to customers.
Doximity, Inc. (DOCS) Q1 2025 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:50 PM ET Doximity, Inc. (NYSE:DOCS ) Q1 2025 Earnings Conference Call August 08, 2024, 17:00 PM ET Company Participants Jeff Tangney - Co-founder and CEO Nate Gross - Co-founder and CSO Anna Bryson - CFO Perry Gold - VP of IR Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Stephanie Davis - Barclays Jared Hass - William Blair John Pinney - Canaccord Genuity Allen Lutz - Bank of America Elizabeth Anderson - Evercore ISI Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Craig Hettenbach - Morgan Stanley Jenny Cao - Truist Securities Stan Berenshteyn - Wells Fargo Securities Jenny Shen - BTIG Operator Good day, everyone, and welcome to the Doximity Fiscal First Quarter 2025 Earnings Call. At this time, I would like to hand things over to Vice President of Investor Relations, Perry Gold.
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Why the Market Dipped But Doximity (DOCS) Gained Today
Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most.
Dr Martens targets growth in US direct-to-customer market
Dr Martens PLC (LSE:DOCS) has published a bare trading update prior to a Thursday AGM. The classic British footwear company said that “trading since the start of this financial year has been in line with expectations and our guidance for (financial 2025) remains unchanged”.
Doximity (DOCS) Ascends While Market Falls: Some Facts to Note
Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.
Dr Martens rating could go either way, depending on US consumer demand - analyst
Dr Martens PLC (LSE:DOCS) stock market rating is on something of a knife edge with analysts at Barclay's keen for visibility over the boot maker's direct-to-consumer sales channel. A less than emphatic recent trading update leaves investors guessing in regards to the company's prospects for the rest of the year.
